During the past decade, Valérie POURCHER conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Valérie POURCHER" are "Covid19" (1 trials) and "HBV" (1 trials). Many other conditions were trialed in "Valérie POURCHER" in a lesser frequency.

Most popular intervention types in "Valérie POURCHER" are "Biological" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Seroprevalence of SARS-CoV-2 infection in patients with HIV infection" (1 trials) and "o receive treatment with anti-CD20 (rituximab or ocrelizumab) and to be vaccinated against hepatitis B" (1 trials). Other intervention names were less common.

The vast majority of trials in "Valérie POURCHER" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Valérie POURCHER". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Valérie POURCHER, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Valérie POURCHER, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".